Recent Price Move Puts Hinge Health In Focus
Hinge Health (HNGE) drew investor attention after a recent daily move of about 6%, adding to gains over the past month and past 3 months. The stock last closed at US$92.56.
Zooming out, Hinge Health has posted a 30 day share price return of 23.89% and a 90 day share price return of 58.28%. The year to date share price return is 103.16% and the 1 year total shareholder return is 65.05%, which points to strong momentum building rather than fading.
Scan momentum plays similar to Hinge Health using our hand picked list of 39 healthcare AI stocks.
After this sharp run, Hinge Health trades at US$92.56 while analyst targets and intrinsic estimates sit much higher on paper. How wide is that gap in practical terms for anyone weighing the current price?
Most Popular Narrative: 2% Overvalued
The most followed Hinge Health narrative pegs fair value at $90.87, just below the current $92.56 share price, which leaves only a narrow valuation gap.
Several research notes highlight new products such as HingeSelect, surgical support, and the Migraine program as potential incremental revenue drivers that support multi year growth frameworks.
Read the complete narrative. Read the complete narrative.
Want to see what is built into that near full valuation for Hinge Health? The narrative focuses on faster top line expansion, rising profitability and a future earnings multiple that assumes those targets hold. This raises the question of which specific revenue and margin paths drive that $90.87 fair value.
Result: Fair Value of $90.87 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors also need to watch for weaker employer or health plan demand for digital MSK solutions, as well as any slowdown in HingeSelect adoption that could challenge this upbeat narrative.
Find out about the key risks to this Hinge Health narrative.
Another View On Hinge Health’s Valuation
The analyst narrative points to Hinge Health trading about 2% above a US$90.87 fair value. Our DCF model presents a very different picture. It suggests a fair value of US$369.58 per share, which is a very large gap above the current US$92.56 price. Which perspective do you consider more accurate?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hinge Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Sentiment around Hinge Health is clearly upbeat, so it makes sense to move quickly, review the data yourself and stress test the assumptions that matter most to you. To see which potential upsides analysts are focusing on, start by checking the 3 key rewards.
Looking For More Ideas Beyond Hinge Health?
If Hinge Health has your attention, do not stop here. Broaden your watchlist with focused stock ideas that match your goals and risk comfort.
- Target potential mispricing by reviewing a curated set of value opportunities through the 45 high quality undervalued stocks.
- Strengthen your income stream by scanning stocks in the 12 dividend fortresses that aim to pair higher yields with resilience.
- Prioritise resilience by checking companies screened for sturdier finances in the list of solid balance sheet and fundamentals (52 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com